Global non-small cell lung cancer treatment market is expected to witness a growth rate of 8.9% to reach US$ 47.6 Bn market size by 2030.

Industry drivers and trends:

Increasing prevalence of lung cancer is major driving factor behind growth of the industry. For instance, according to American Cancer Society (ASC), in 2022, there were ~236,740 new cases of lung cancer (117,910 in men and 118,830 in women) in the US.. Moreover, industry developments such as product launches,  acquisitions and collaborations are expected to support global non-small cell lung cancer treatment market growth over the forecast period. For instance, in May 2021, US Food and Drug Administration (FDA) approved Lumakras (Sotarasib) the first and only targeted treatment for patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer.

• Lung cancer traditional treatment algorithm includes options such as surgery, radiotherapy, and chemotherapy. However newer treatment options have emerged over the past few years such as immunotherapy, and targeted therapy which have shown tremendous growth over the past few years
• Global non-small cell lung cancer treatment market is a consolidated industry with a few organizations occupying majority of the market share. These organizations provide traditional (generic chemotherapy) as well as newer treatment options such as immunotherapy
• Some of these organizations are Eli Lilly and Company, Merck & Co., Inc., Pfizer Inc., and AstraZeneca plc among others

Key Takeaways:

• North America region occupies highest market share in the global non-small cell lung cancer treatment market followed by Europe
• Immunotherapy and targeted therapy treatment types are expected to show significant growth over the forecast period owing to research and development
• Advancements in diagnostic technologies is further expected to support global non-small cell lung cancer market growth over the forecast period
• For instance, technologies such as Artificial Intelligence are being used to improve lung cancer diagnosis rates, and early detection.

Segments covered in the global non-small cell lung cancer treatment market report:

The global non-small cell lung cancer treatment market is segmented based on treatment type, marketed brand , distribution channel, and region as follows:

• Treatment Type (Revenue, USD Billion; 2022–2030)
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others
• Marketed Brand (Revenue, USD Billion; 2022–2030)
  • Bevacizumab (Avastin)
  • Necitumumab (Portrazza)
  • Ramucirumab (Cyramza)
  • Nivolumab (Opdivo)
  • Atezolizumab (Tecentriq)
  • Others
• Distribution Channel (Revenue, USD Billion; 2022–2030)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region (Revenue, USD Billion; 2022–2030)
  • North America 
    • U.S.
    • Canada
  • Europe 
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific 
    • China
    • Japan
    • South Korea
    • India
    • ASEAN
    • Rest of APAC
  • Latin America 
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa 
    • Saudi Arabia
    • UAE
    • Rest of MEA

Definition:

The Non-small Cell Lung Cancer Treatment Market refers to the pharmaceutical and healthcare sector that focuses on the development, production, and distribution of medical therapies, drugs, and interventions aimed at diagnosing, managing, and treating Non-small Cell Lung Cancer (NSCLC), a type of lung cancer that accounts for the majority of lung cancer cases. This market encompasses a wide range of treatments, including chemotherapy, targeted therapies, immunotherapies, radiation therapy, and surgical interventions, all designed to combat NSCLC and improve patients' quality of life and survival rates.